Clinical Trial Update: Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled trial evaluating fostamatinib for COVID-19 has completed enrollment and study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia
• Pneumonia Viral
• Sars
• Sars Pneumonia

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Status: COMPLETED